Abstracts For Oral Presentation 2018



Maximizing Clinical Trial Design in Evaluating Safety and Efficacy of Microbiota-Based Therapies for Recurrent Clostridium difficile Infection:  The Added Insight of Microbiome Profiling and the Microbiome Health Index in Two Phase 2 Controlled Trials of RBX2660

Sarah Mische PhD1, Robert Orenstein DO2, Erik Dubberke3, Sahil Khanna MBBS4, Gail Hecht MD5 , Herbert Dupont MD6, Christine H. Lee7,  Dale N. Gerding, MD8,  Ken Blount PhD1

1Rebiotix, Inc. Roseville, MN; 2Division of Infectious Diseases, Mayo Clinic in Arizona, Phoenix, AZ, USA; 3Department of Internal Medicine, Washington University of St. Louis, St. Louis, MO; 4Division of Gastroenterology and Hepatology,  Mayo Clinic, Rochester, MN, USA; 5Division of Gastroenterology and Nutrition, Loyola University Medical Center, Chicago, IL, USA; 6University of Texas Health Science Center, Houston, TX, USA;  7Hamilton Regional Laboratory Medicine Program, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, Vancouver Island Health Authority, Victoria, Department of Pathology and Laboratory Medicine, University of British Columbia, BC, Canada; 8Loyola University Stritch School of Medicine, Maywood, IL, Edward Hines Jr. VA Hospital, Hines, IL, USA


“Perception of Quality of Life Among People Experiencing or Having Experienced a Clostridium difficile Infection in the United States: Qualitative Review of Respondents Verbatim”

Da Volterra is a privately-held biotechnology company, headquartered in Paris, France. The company was created in 2000 by Professor Antoine Andremont whose research is dedicated to understanding the impact of antibiotics on the intestinal flora. He is one of the most renowned thought leaders in the field of antibiotic resistance and a pioneer in conceiving strategies to tackle antibiotic resistance at the root. Da Volterra headquarters is located in Paris, Le Dorian B1 – 4e étage ,  172 rue de Charonne, 75011 PARIS  FRANCE



“Evaluation of Clostridium difficile burden using high-resolution gut microbiome profiling”

James Robert White, PhD

The human intestinal tract contains thousands of unique microbial species that in aggregate constitute the gut microbiome. To study these microorganisms at the community level, scientists employ DNA sequencing techniques that allow for sampling of the total bacterial diversity within a stool specimen, including known pathogens such as Clostridium difficile. Here, we will provide an overview of advanced microbiome profiling strategies and apply these techniques to characterization of the burden of C. difficile in critical patient populations. Finally, we will describe gut bacterial species that show consistent negative correlations with C. difficile, suggesting the potential for a protective effect against C. difficile infection.

Resphera Biosciences is developing innovative computational and statistical approaches to microbiome sequence analysis that deliver clinically relevant results, enabling doctors and scientists to better identify potential pathogens and characterize dysbiosis in complex microbial environments.  Resphera Biosciences is located  in Baltimore, MD USA